Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
McKesson
Merck
McKinsey
Colorcon

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Cenicriviroc

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Cenicriviroc: Patents, clinical trial progress, indications

Cenicriviroc is an investigational drug.

There have been 12 clinical trials for Cenicriviroc. The most recent clinical trial was a Phase 2 trial, which was initiated on April 20th 2017.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Liver Cirrhosis. The leading clinical trial sponsors are Tobira Therapeutics, Inc., Novartis Pharmaceuticals, and Allergan.

There are five US patents protecting this investigational drug and forty-two international patents.

Recent Clinical Trials for Cenicriviroc
TitleSponsorPhase
Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis. (TANDEM)AllerganPhase 2
Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis. (TANDEM)Novartis PharmaceuticalsPhase 2
AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASHTobira Therapeutics, Inc.Phase 3

See all Cenicriviroc clinical trials

Clinical Trial Summary for Cenicriviroc

Top disease conditions for Cenicriviroc
Top clinical trial sponsors for Cenicriviroc

See all Cenicriviroc clinical trials

US Patents for Cenicriviroc

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Cenicriviroc   Start Trial Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate Tobira Therapeutics, Inc. (South San Francisco, CA)   Start Trial
Cenicriviroc   Start Trial Bicyclic compound, production and use thereof Takeda Pharmaceutical Company Limited (Osaka, JP)   Start Trial
Cenicriviroc   Start Trial Bicyclic compound, production and use thereof Tobira Therapeutics, Inc. (Princeton, NJ)   Start Trial
Cenicriviroc   Start Trial Bicyclic compound, production and use thereof Tobira Therapeutics, Inc. (South San Francisco, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Cenicriviroc

Drugname Country Document Number Estimated Expiration Related US Patent
Cenicriviroc Australia 2017321594 2036-08-31   Start Trial
Cenicriviroc Brazil 112019003987 2036-08-31   Start Trial
Cenicriviroc Canada 3034606 2036-08-31   Start Trial
Cenicriviroc China 110167550 2036-08-31   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
McKesson
Medtronic
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.